🚀 VC round data is live in beta, check it out!
Intensity Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Intensity Therapeutics and similar public comparables like Oncoinvent, Wellgistics Health, Klaria Pharma Holding, VYNE Therapeutics and more.
Intensity Therapeutics Overview
About Intensity Therapeutics
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
Founded
2012
HQ
Employees
16
Website
Sectors
Financials (LTM)
EV
$13M
Intensity Therapeutics Financials
Intensity Therapeutics reported last 12-month revenue of —.
In the same LTM period, Intensity Therapeutics generated — in gross profit and had net loss of ($12M).
Revenue (LTM)
Intensity Therapeutics P&L
In the most recent fiscal year, Intensity Therapeutics reported revenue of — and EBITDA of ($16M).
Intensity Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($16M) | XXX | XXX | XXX |
| Net Profit | ($12M) | XXX | ($16M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Intensity Therapeutics Stock Performance
Intensity Therapeutics has current market cap of $20M, and enterprise value of $13M.
Market Cap Evolution
Intensity Therapeutics' stock price is $7.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $20M | 0.0% | XXX | XXX | XXX | $-6.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIntensity Therapeutics Valuation Multiples
Intensity Therapeutics trades at (0.8x) EV/EBITDA.
Intensity Therapeutics Financial Valuation Multiples
As of March 18, 2026, Intensity Therapeutics has market cap of $20M and EV of $13M.
Equity research analysts estimate Intensity Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Intensity Therapeutics has a P/E ratio of (1.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20M | XXX | $20M | XXX | XXX | XXX |
| EV (current) | $13M | XXX | $13M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.8x) | XXX | XXX | XXX |
| EV/EBIT | (1.1x) | XXX | (0.8x) | XXX | XXX | XXX |
| P/E | (1.7x) | XXX | (1.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Intensity Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Intensity Therapeutics Margins & Growth Rates
Intensity Therapeutics' revenue in the last fiscal year grew by —.
Intensity Therapeutics' revenue per employee in the last FY averaged $0.0M.
Intensity Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Intensity Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Oncoinvent | XXX | XXX | XXX | XXX | XXX | XXX |
| Wellgistics Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Klaria Pharma Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| VYNE Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Xintela | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Intensity Therapeutics M&A Activity
Intensity Therapeutics acquired XXX companies to date.
Last acquisition by Intensity Therapeutics was on XXXXXXXX, XXXXX. Intensity Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Intensity Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIntensity Therapeutics Investment Activity
Intensity Therapeutics invested in XXX companies to date.
Intensity Therapeutics made its latest investment on XXXXXXXX, XXXXX. Intensity Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Intensity Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Intensity Therapeutics
| When was Intensity Therapeutics founded? | Intensity Therapeutics was founded in 2012. |
| Where is Intensity Therapeutics headquartered? | Intensity Therapeutics is headquartered in United States. |
| How many employees does Intensity Therapeutics have? | As of today, Intensity Therapeutics has over 16 employees. |
| Who is the CEO of Intensity Therapeutics? | Intensity Therapeutics' CEO is Lewis H. Bender. |
| Is Intensity Therapeutics publicly listed? | Yes, Intensity Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Intensity Therapeutics? | Intensity Therapeutics trades under INTS ticker. |
| When did Intensity Therapeutics go public? | Intensity Therapeutics went public in 2023. |
| Who are competitors of Intensity Therapeutics? | Intensity Therapeutics main competitors are Oncoinvent, Wellgistics Health, Klaria Pharma Holding, VYNE Therapeutics. |
| What is the current market cap of Intensity Therapeutics? | Intensity Therapeutics' current market cap is $20M. |
| Is Intensity Therapeutics profitable? | No, Intensity Therapeutics is not profitable. |
| What is the current net income of Intensity Therapeutics? | Intensity Therapeutics' last 12 months net income is ($12M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.